ImmunoCellular Therapeutics to Present at Future Leaders in the Biotech Industry Conference
April 18, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) News), a clinical stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that Manish Singh, PhD, President and Chief Executive Officer of the Company will be presenting at the 19th Annual Future Leaders in the Biotech Industry Conference in the Millennium Broadway Hotel & Conference Center in New York City. ImmunoCellular will be presenting on Friday, April 20th, 2012 at 2:30 pm EST in presentation room 302/303.

ImmunoCellular Brings Second Manufacturing Site On-line
April 4, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) News), a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that the transfer of technology from the University of Pennsylvania to a second manufacturing site is complete. Last October, IMUC entered into an arrangement with Progenitor Cell Therapy, LLC,(PCT) a wholly owned subsidiary of NeoStem, Inc. (NYSE AMEX: NBS), to produce ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma (GBM), for IMUC’s Phase II clinical trial.

ImmunoCellular Therapeutics to Present on Cancer Stem Cell Targeting at the AACR Annual Meeting
March 27, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) News), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the Company will deliver a presentation on the identification and characterization of immunogenic epitopes from CD133 and their potential for use to immunologically target cancer stem cells (CSCs) at the Annual Meeting of the American Association for Cancer Research, which will be held from March 31 to April 4, 2012 at McCormick Place in Chicago, Illinois.

ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh
March 22, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) News) today announced that it has entered into an agreement with University of Pittsburgh (Pitt) under which Pitt has licensed to the Company intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. This agreement grants a world-wide exclusive license to the Pitt intellectual property for ovarian and pancreatic cancers; and a world-wide non-exclusive license to the Pitt intellectual property for brain cancer. The financial terms of the agreement were not disclosed.

ImmunoCellular Therapeutics to Present at Cowen and Company's 32nd Annual Health Care Conference
March 19, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC)today announced that its proprietary method for manufacturing ICT-107, its lead dendritic cell (DC) based vaccine for the treatment of glioblastoma multiforme (GBM), has demonstrated meaningfully enhanced efficiency, consistency and convenience, compared to other methods for producing DC-based immunotherapies.

ImmunoCellular to Present at the 6th Annual International BIO-Europe Spring 2012 Conference
March 16, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) News), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Peter Ho Ph.D., Director of Business Development and Licensing, will be presenting at the Annual Partnering Conference at the Amsterdam RAI Convention Center in Amsterdam on Tuesday, March 20, 2012 at 10:45am CET. The BIO-Europe Spring Conference provides life science companies with promising partnering opportunities.

ImmunoCellular Therapeutics Reports Manufacturing Process Data for ICT-107
March 12, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC)today announced that its proprietary method for manufacturing ICT-107, its lead dendritic cell (DC) based vaccine for the treatment of glioblastoma multiforme (GBM), has demonstrated meaningfully enhanced efficiency, consistency and convenience, compared to other methods for producing DC-based immunotherapies.

ImmunoCellular Therapeutics to Present at Cowen and Company's 32nd Annual Health Care Conference
March 5, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Cowen and Company's 32nd Annual Health Care Conference on Monday, March 5th, at 2:10 p.m., on the 4th floor, Salon C of the Marriot Hotel in Boston, Massachusetts. The presentation will be webcast following registration at the web address below: http://wsw.com/webcast/cowen6/imuc

ImmunoCellular Therapeutics Licenses Mesothelin Cancer Antigen from Johns Hopkins University
February 29, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) today announced that it has entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The terms of the agreement were not disclosed.

ImmunoCellular Therapeutics Announces Licensing Agreement with University of Pennsylvania for Enhanced Dendritic-Cell Production Technology
February 21, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC) today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells (DCs). The license covers the application of this technology to the development of therapeutics for all indications except breast cancer and ductal carcinoma in situ. The terms of the agreement were not disclosed.

ImmunoCellular Therapeutics Issues Letter to Shareholders
February 9, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its president and CEO, Manish Singh Ph.D., will be presenting at the upcoming 14th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 13th, 2012 at 1:00 pm. The presentation will be webcast following registration at the web address below: http://www.veracast.com/webcasts/bio/ceoinvestor2012/06110111.cfm

ImmunoCellular Therapeutics Issues Letter to Shareholders
February 7, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), issued the following Letter to Shareholders today:

ImmunoCellular Therapeutics Receives Notice of Allowance of Cancer Stem Cell Targeting Patent
February 1, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells (CSC). ImmunoCellular received notice from the U.S. Patent and Trademark Office that a patent titled "Cancer Stem Cell Antigen Vaccines and Methods," which covers various methods of using dendritic cells combined with antigens derived from glioblastoma CSCs for the treatment of GBM has been allowed.

ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference
January 30, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012. Dr. Singh's presentation will be titled "Targeting Cancer Stem Cells Via Immunotherapy" and will include an overview of ImmunoCellular's clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma
January 23, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company has initiated the trial in 23 centers and has received Institutional Review Board (IRB) approval from a total of 24 trial sites. The trial is expected to enroll approximately 160-200 patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There are 115 patients enrolled in the study to date, ahead of the Company's schedule. Enrollment for the trial is expected to be completed by the second quarter of 2012 and an interim analysis is expected when 50% of events (32 deaths) have been observed.

ImmunoCellular Therapeutics to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
January 17th, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, today announced that its President and CEO, Manish Singh Ph.D., will present at the Noble Financial Capital Markets Eighth Annual Equity Conference, being held at the Hard Rock Hotel in Hollywood, Florida from January 16-18, 2012.

ImmunoCellular Therapeutics Prices Underwritten Offering
January 10th, 2012
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), an emerging biotechnology company focused on developing novel-immune-based therapies, announced today the pricing of an underwritten offering of 9,489,436 units, each unit consisting of one share of its common stock and a warrant to purchase one half of a share of its common stock, at a public offering price of $1.10 per unit. ImmunoCellular expects to receive net proceeds of approximately $9.4 million, after deducting the underwriting discount and estimated offering expenses. The warrants will have a five-year term and an exercise price equal to $1.41 per share. The offering is expected to close on January 13, 2012, subject to customary closing conditions.

Press Archives